Blueprint Medicines Corp.

How big is Blueprint Medicines Corp.?

As of Jun 18, Blueprint Medicines Corp. has a market capitalization of $8.29 billion, with net sales of $562.12 million and a net profit of -$155.73 million over the latest four quarters. Shareholder's funds are $298.67 million, and total assets amount to $1.18 billion.

As of Jun 18, Blueprint Medicines Corp. has a market capitalization of 8,292.13 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the company reported net sales of 562.12 million for the latest four quarters, while the net profit for the same period was -155.73 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 298.67 million and total assets amounting to 1,179.81 million.

What does Blueprint Medicines Corp. do?

Blueprint Medicines Corporation is a biopharmaceutical company focused on treating genomically defined diseases caused by abnormal kinase activation. As of March 2025, it reported net sales of $149 million and has a market capitalization of approximately $8.29 billion.

Overview: <BR>Blueprint Medicines Corporation is a biopharmaceutical company that focuses on patients with genomically defined diseases driven by abnormal kinase activation, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 149 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 8,292.13 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.21 <BR>Return on Equity: -45.52% <BR>Price to Book: 24.24<BR><BR>Contact Details: <BR>Address: 45 Sidney St, CAMBRIDGE MA : 02139-4133 <BR>Tel: ['1 617 3747580', '1 617 7146674'] <BR>Fax: 1 302 6555049 <BR>Website: http://www.blueprintmedicines.com/

Should I buy, sell or hold Blueprint Medicines Corp.?

Who are in the management team of Blueprint Medicines Corp.?

As of March 2022, the management team of Blueprint Medicines Corp. includes CEO Jeffrey Albers and Independent Chairman Daniel Lynch, along with several independent directors: Alexis Borisy, Lonnel Coats, George Demetri, Mark Goldberg, and Nicholas Lydon. The team consists of both executive leadership and independent directors.

As of March 2022, the management team of Blueprint Medicines Corp. includes the following individuals:<BR><BR>- Mr. Daniel Lynch, who serves as the Independent Chairman of the Board.<BR>- Mr. Jeffrey Albers, who is the Chief Executive Officer and a Director.<BR>- Mr. Alexis Borisy, who is a Director.<BR>- Mr. Lonnel Coats, who is an Independent Director.<BR>- Dr. George Demetri, who is an Independent Director.<BR>- Dr. Mark Goldberg, who is an Independent Director.<BR>- Dr. Nicholas Lydon, who is an Independent Director.<BR><BR>In summary, the management team is comprised of a mix of executive leadership and independent directors.

Is Blueprint Medicines Corp. overvalued or undervalued?

As of October 28, 2021, Blueprint Medicines Corp. is considered overvalued with a risky valuation grade, indicated by high Price to Book and EV to Capital Employed ratios, a negative EV to EBITDA compared to peers, and despite a strong year-to-date return, its current price level is not justified.

As of 28 October 2021, the valuation grade for Blueprint Medicines Corp. has moved from fair to risky, indicating a shift towards a more negative outlook. Based on the available metrics, the company appears to be overvalued. The Price to Book Value stands at 24.13, while the EV to Capital Employed is 20.12, both suggesting a high valuation relative to its underlying assets. Additionally, the EV to Sales ratio of 14.82 further supports this assessment of overvaluation.<BR><BR>In comparison to its peers, Blueprint Medicines Corp. has a significantly negative EV to EBITDA of -52.59, while BridgeBio Pharma, Inc. shows a less severe -19.7279, indicating that Blueprint is underperforming relative to its industry. Moreover, Elanco Animal Health, Inc. is considered expensive with a P/E ratio of 19.2485, highlighting that Blueprint's valuation metrics are not competitive. Despite a strong year-to-date return of 48.43% compared to the S&P 500's 12.22%, the overall valuation suggests that the stock is not justified at its current price level.

Is Blueprint Medicines Corp. technically bullish or bearish?

As of June 4, 2025, Blueprint Medicines Corp. is in a bullish trend supported by strong technical indicators, despite a bearish weekly RSI suggesting short-term caution, with year-to-date returns of 48.43% significantly outperforming the S&P 500's 12.22%.

As of 4 June 2025, the technical trend for Blueprint Medicines Corp. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, while the Bollinger Bands also indicate bullishness in both periods. Moving averages are bullish on the daily chart, and Dow Theory confirms a bullish trend on both weekly and monthly levels. However, the weekly RSI is bearish, which suggests some short-term weakness. <BR><BR>In terms of performance, the stock has returned 48.43% year-to-date compared to the S&P 500's 12.22%, and over three years, it has outperformed the benchmark with a return of 141.76% versus 70.41%. Overall, the technical indicators point to a bullish stance, albeit with some caution due to the bearish weekly RSI.